Annual Net Income
-$7.60 M
+$13.29 M+63.62%
31 December 2023
Summary:
GT Biopharma annual net profit is currently -$7.60 million, with the most recent change of +$13.29 million (+63.62%) on 31 December 2023. During the last 3 years, it has risen by +$20.70 million (+73.15%). GTBP annual net income is now -177.77% below its all-time high of $9.77 million, reached on 31 December 2016.GTBP Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$3.41 M
+$299.00 K+8.06%
30 September 2024
Summary:
GT Biopharma quarterly net profit is currently -$3.41 million, with the most recent change of +$299.00 thousand (+8.06%) on 30 September 2024. Over the past year, it has dropped by -$995.00 thousand (-41.18%). GTBP quarterly net income is now -112.70% below its all-time high of $26.86 million, reached on 30 June 2015.GTBP Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$12.35 M
-$995.00 K-8.76%
30 September 2024
Summary:
GT Biopharma TTM net profit is currently -$12.35 million, with the most recent change of -$995.00 thousand (-8.76%) on 30 September 2024. Over the past year, it has dropped by -$2.13 million (-20.84%). GTBP TTM net income is now -189.69% below its all-time high of $13.77 million, reached on 31 March 2016.GTBP TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +63.6% | -41.2% | -20.8% |
| 3 y3 years | +73.2% | +37.5% | +73.3% |
| 5 y5 years | +97.1% | +88.6% | +70.2% |
GTBP Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +86.9% | -1402.6% | +81.1% | -62.5% | +78.7% |
| 5 y | 5 years | at high | +97.1% | -1402.6% | +88.6% | -62.5% | +78.7% |
| alltime | all time | -177.8% | +97.1% | -112.7% | +98.5% | -189.7% | +95.3% |
GT Biopharma Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.41 M(-8.1%) | -$12.35 M(+8.8%) |
| June 2024 | - | -$3.71 M(+63.7%) | -$11.35 M(+17.8%) |
| Mar 2024 | - | -$2.27 M(-23.5%) | -$9.64 M(+26.8%) |
| Dec 2023 | -$7.60 M(-63.6%) | -$2.96 M(+22.6%) | -$7.60 M(-25.7%) |
| Sept 2023 | - | -$2.42 M(+21.3%) | -$10.22 M(-30.4%) |
| June 2023 | - | -$1.99 M(+777.5%) | -$14.68 M(-6.3%) |
| Mar 2023 | - | -$227.00 K(-95.9%) | -$15.67 M(-25.0%) |
| Dec 2022 | -$20.88 M(-64.0%) | -$5.58 M(-18.8%) | -$20.88 M(-37.3%) |
| Sept 2022 | - | -$6.88 M(+131.0%) | -$33.32 M(+4.5%) |
| June 2022 | - | -$2.98 M(-45.2%) | -$31.89 M(-5.6%) |
| Mar 2022 | - | -$5.44 M(-69.8%) | -$33.78 M(-41.8%) |
| Dec 2021 | -$58.01 M(+105.0%) | -$18.02 M(+230.5%) | -$58.01 M(+25.3%) |
| Sept 2021 | - | -$5.45 M(+12.2%) | -$46.28 M(+5.9%) |
| June 2021 | - | -$4.86 M(-83.6%) | -$43.70 M(-22.3%) |
| Mar 2021 | - | -$29.68 M(+371.8%) | -$56.27 M(+98.8%) |
| Dec 2020 | -$28.30 M(-26.8%) | -$6.29 M(+118.7%) | -$28.30 M(+20.5%) |
| Sept 2020 | - | -$2.88 M(-83.5%) | -$23.48 M(-53.5%) |
| June 2020 | - | -$17.42 M(+920.0%) | -$50.48 M(+40.8%) |
| Mar 2020 | - | -$1.71 M(+16.2%) | -$35.84 M(-7.3%) |
| Dec 2019 | -$38.65 M(-85.1%) | -$1.47 M(-95.1%) | -$38.65 M(-6.7%) |
| Sept 2019 | - | -$29.88 M(+971.3%) | -$41.41 M(-83.3%) |
| June 2019 | - | -$2.79 M(-38.2%) | -$247.31 M(-2.5%) |
| Mar 2019 | - | -$4.51 M(+6.6%) | -$253.60 M(-2.2%) |
| Dec 2018 | -$259.19 M(+79.8%) | -$4.23 M(-98.2%) | -$259.19 M(-0.7%) |
| Sept 2018 | - | -$235.78 M(+2496.4%) | -$260.98 M(+67.5%) |
| June 2018 | - | -$9.08 M(-10.0%) | -$155.82 M(+4.4%) |
| Mar 2018 | - | -$10.09 M(+67.5%) | -$149.21 M(+3.5%) |
| Dec 2017 | -$144.17 M(-1576.0%) | -$6.03 M(-95.4%) | -$144.17 M(+2.3%) |
| Sept 2017 | - | -$130.63 M(+5203.5%) | -$140.97 M(+908.4%) |
| June 2017 | - | -$2.46 M(-51.3%) | -$13.98 M(+40.2%) |
| Mar 2017 | - | -$5.06 M(+78.8%) | -$9.97 M(-202.1%) |
| Dec 2016 | $9.77 M(-145.6%) | -$2.83 M(-22.1%) | $9.77 M(-172.4%) |
| Sept 2016 | - | -$3.63 M(-335.3%) | -$13.49 M(+16.8%) |
| June 2016 | - | $1.54 M(-89.5%) | -$11.55 M(-183.9%) |
| Mar 2016 | - | $14.68 M(-156.3%) | $13.77 M(-164.2%) |
| Dec 2015 | -$21.43 M(-8.8%) | -$26.08 M(+1441.5%) | -$21.43 M(+53.3%) |
| Sept 2015 | - | -$1.69 M(-106.3%) | -$13.98 M(-15.3%) |
| June 2015 | - | $26.86 M(-230.9%) | -$16.51 M(-62.2%) |
| Mar 2015 | - | -$20.52 M(+10.1%) | -$43.63 M(+85.8%) |
| Dec 2014 | -$23.49 M(+4588.4%) | -$18.64 M(+341.6%) | -$23.49 M(+351.1%) |
| Sept 2014 | - | -$4.22 M(+1510.7%) | -$5.21 M(+298.7%) |
| June 2014 | - | -$262.00 K(-29.4%) | -$1.31 M(-3.3%) |
| Mar 2014 | - | -$371.00 K(+4.8%) | -$1.35 M(+164.2%) |
| Dec 2013 | -$501.00 K(-90.3%) | -$354.00 K(+11.0%) | -$511.00 K(-44.3%) |
| Sept 2013 | - | -$319.00 K(+4.2%) | -$918.00 K(-54.1%) |
| June 2013 | - | -$306.00 K(-165.4%) | -$2.00 M(-51.1%) |
| Mar 2013 | - | $468.00 K(-161.5%) | -$4.09 M(-20.9%) |
| Dec 2012 | -$5.17 M(+39.8%) | -$761.00 K(-45.6%) | -$5.17 M(-6.8%) |
| Sept 2012 | - | -$1.40 M(-41.5%) | -$5.55 M(+34.5%) |
| June 2012 | - | -$2.40 M(+289.4%) | -$4.13 M(+72.4%) |
| Mar 2012 | - | -$615.00 K(-46.0%) | -$2.39 M(-35.4%) |
| Dec 2011 | -$3.70 M(+23.5%) | -$1.14 M(-5047.8%) | -$3.70 M(+14.8%) |
| Sept 2011 | - | $23.00 K(-103.5%) | -$3.22 M(-16.9%) |
| June 2011 | - | -$662.00 K(-65.6%) | -$3.88 M(+37.6%) |
| Mar 2011 | - | -$1.92 M(+190.5%) | -$2.82 M(-5.9%) |
| Dec 2010 | -$3.00 M(+33.3%) | -$662.00 K(+4.6%) | -$3.00 M(-18.4%) |
| Sept 2010 | - | -$633.00 K(-258.6%) | -$3.67 M(+11.0%) |
| June 2010 | - | $399.00 K(-119.0%) | -$3.31 M(-18.6%) |
| Mar 2010 | - | -$2.10 M(+57.0%) | -$4.06 M(+80.7%) |
| Dec 2009 | -$2.25 M(-55.1%) | -$1.34 M(+398.9%) | -$2.25 M(+50.6%) |
| Sept 2009 | - | -$268.00 K(-24.5%) | -$1.49 M(-26.2%) |
| June 2009 | - | -$355.00 K(+24.1%) | -$2.02 M(-51.9%) |
| Mar 2009 | - | -$286.00 K(-50.9%) | -$4.20 M(-16.1%) |
| Dec 2008 | -$5.01 M(-1162.8%) | -$582.00 K(-27.0%) | -$5.01 M(+20.8%) |
| Sept 2008 | - | -$797.00 K(-68.5%) | -$4.14 M(+19.5%) |
| June 2008 | - | -$2.53 M(+131.5%) | -$3.47 M(-2396.0%) |
| Mar 2008 | - | -$1.09 M(-490.7%) | $151.00 K(-67.9%) |
| Dec 2007 | $471.00 K(-109.5%) | $280.00 K(-333.3%) | $471.00 K(-116.7%) |
| Sept 2007 | - | -$120.00 K(-111.1%) | -$2.83 M(-15.9%) |
| June 2007 | - | $1.08 M(-240.2%) | -$3.36 M(-33.1%) |
| Mar 2007 | - | -$774.00 K(-74.4%) | -$5.02 M(+1.7%) |
| Dec 2006 | -$4.94 M(+58.9%) | -$3.02 M(+362.2%) | -$4.94 M(+18.6%) |
| Sept 2006 | - | -$653.00 K(+12.8%) | -$4.16 M(+8.7%) |
| June 2006 | - | -$579.00 K(-16.1%) | -$3.83 M(+7.9%) |
| Mar 2006 | - | -$690.00 K(-69.2%) | -$3.55 M(+14.2%) |
| Dec 2005 | -$3.11 M | -$2.24 M(+605.0%) | -$3.11 M(+80.1%) |
| Sept 2005 | - | -$318.00 K(+6.0%) | -$1.73 M(+18.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2005 | - | -$300.00 K(+20.5%) | -$1.46 M(-37.9%) |
| Mar 2005 | - | -$249.00 K(-71.0%) | -$2.35 M(-12.8%) |
| Dec 2004 | -$2.70 M(+241.1%) | -$859.00 K(+1520.8%) | -$2.70 M(+31.0%) |
| Sept 2004 | - | -$53.00 K(-95.6%) | -$2.06 M(-4.2%) |
| June 2004 | - | -$1.19 M(+101.2%) | -$2.15 M(+74.1%) |
| Mar 2004 | - | -$593.00 K(+169.5%) | -$1.24 M(+56.1%) |
| Dec 2003 | -$791.00 K(-3.8%) | -$220.00 K(+52.8%) | -$791.00 K(+7.5%) |
| Sept 2003 | - | -$144.00 K(-48.2%) | -$736.00 K(-17.3%) |
| June 2003 | - | -$278.00 K(+86.6%) | -$890.00 K(+15.1%) |
| Mar 2003 | - | -$149.00 K(-9.7%) | -$773.00 K(-6.0%) |
| Dec 2002 | -$822.00 K(-76.5%) | -$165.00 K(-44.6%) | -$822.00 K(-6.9%) |
| Sept 2002 | - | -$298.00 K(+85.1%) | -$883.00 K(-7.2%) |
| June 2002 | - | -$161.00 K(-18.7%) | -$952.00 K(-62.6%) |
| Mar 2002 | - | -$198.00 K(-12.4%) | -$2.55 M(-27.2%) |
| Dec 2001 | -$3.50 M(-25.4%) | -$226.00 K(-38.4%) | -$3.50 M(-26.6%) |
| Sept 2001 | - | -$367.00 K(-79.1%) | -$4.77 M(-13.6%) |
| June 2001 | - | -$1.76 M(+53.0%) | -$5.52 M(+13.5%) |
| Mar 2001 | - | -$1.15 M(-23.3%) | -$4.86 M(+3.8%) |
| Dec 2000 | -$4.68 M(+4.2%) | -$1.50 M(+33.7%) | -$4.68 M(+27.2%) |
| Sept 2000 | - | -$1.12 M(+1.6%) | -$3.68 M(+0.5%) |
| June 2000 | - | -$1.10 M(+13.7%) | -$3.66 M(-16.0%) |
| Mar 2000 | - | -$968.00 K(+95.6%) | -$4.36 M(-5.0%) |
| Dec 1999 | -$4.50 M(-36.7%) | -$495.00 K(-55.0%) | -$4.59 M(-24.7%) |
| Sept 1999 | - | -$1.10 M(-38.9%) | -$6.10 M(-14.1%) |
| June 1999 | - | -$1.80 M(+50.0%) | -$7.10 M(+10.9%) |
| Mar 1999 | - | -$1.20 M(-40.0%) | -$6.40 M(-8.6%) |
| Dec 1998 | -$7.10 M(+36.5%) | -$2.00 M(-4.8%) | -$7.00 M(+14.8%) |
| Sept 1998 | - | -$2.10 M(+90.9%) | -$6.10 M(+13.0%) |
| June 1998 | - | -$1.10 M(-38.9%) | -$5.40 M(-5.3%) |
| Mar 1998 | - | -$1.80 M(+63.6%) | -$5.70 M(+9.6%) |
| Dec 1997 | -$5.20 M(-13.3%) | -$1.10 M(-21.4%) | -$5.20 M(-7.1%) |
| Sept 1997 | - | -$1.40 M(0.0%) | -$5.60 M(0.0%) |
| June 1997 | - | -$1.40 M(+7.7%) | -$5.60 M(-1.8%) |
| Mar 1997 | - | -$1.30 M(-13.3%) | -$5.70 M(-3.4%) |
| Dec 1996 | -$6.00 M(-32.6%) | -$1.50 M(+7.1%) | -$5.90 M(-4.8%) |
| Sept 1996 | - | -$1.40 M(-6.7%) | -$6.20 M(-35.4%) |
| June 1996 | - | -$1.50 M(0.0%) | -$9.60 M(0.0%) |
| Mar 1996 | - | -$1.50 M(-16.7%) | -$9.60 M(+7.9%) |
| Dec 1995 | -$8.90 M(+58.9%) | -$1.80 M(-62.5%) | -$8.90 M(+12.7%) |
| Sept 1995 | - | -$4.80 M(+220.0%) | -$7.90 M(+5.3%) |
| June 1995 | - | -$1.50 M(+87.5%) | -$7.50 M(+21.0%) |
| Mar 1995 | - | -$800.00 K(0.0%) | -$6.20 M(+10.7%) |
| Dec 1994 | -$5.60 M(+273.3%) | -$800.00 K(-81.8%) | -$5.60 M(+14.3%) |
| Sept 1994 | - | -$4.40 M(+2100.0%) | -$4.90 M(+444.4%) |
| June 1994 | - | -$200.00 K(0.0%) | -$900.00 K(-43.8%) |
| Mar 1994 | - | -$200.00 K(+100.0%) | -$1.60 M(+14.3%) |
| Dec 1993 | -$1.50 M(+400.0%) | -$100.00 K(-75.0%) | -$1.40 M(-6.7%) |
| Sept 1993 | - | -$400.00 K(-55.6%) | -$1.50 M(+36.4%) |
| June 1993 | - | -$900.00 K(+350.0%) | -$1.10 M(+175.0%) |
| Dec 1992 | -$300.00 K(+50.0%) | -$200.00 K(+100.0%) | -$400.00 K(+33.3%) |
| June 1992 | - | -$100.00 K(0.0%) | -$300.00 K(0.0%) |
| Mar 1992 | - | -$100.00 K(0.0%) | -$300.00 K(+50.0%) |
| Dec 1991 | -$200.00 K(-122.2%) | -$100.00 K(0.0%) | -$200.00 K(-200.0%) |
| June 1991 | - | -$100.00 K(-150.0%) | $200.00 K(-80.0%) |
| Dec 1990 | $900.00 K(+28.6%) | $200.00 K(+100.0%) | $1.00 M(+11.1%) |
| Sept 1990 | - | $100.00 K(-75.0%) | $900.00 K(+12.5%) |
| June 1990 | - | $400.00 K(+33.3%) | $800.00 K(0.0%) |
| Mar 1990 | - | $300.00 K(+200.0%) | $800.00 K(+14.3%) |
| Dec 1989 | $700.00 K(+600.0%) | $100.00 K(-75.0%) | $700.00 K(+16.7%) |
| June 1989 | - | $400.00 K(+100.0%) | $600.00 K(+100.0%) |
| Mar 1989 | - | $200.00 K(>+9900.0%) | $300.00 K(+200.0%) |
| Dec 1988 | $100.00 K(-66.7%) | $0.00(-100.0%) | $100.00 K(0.0%) |
| June 1988 | - | $100.00 K(0.0%) | $100.00 K(-50.0%) |
| Dec 1987 | $300.00 K(-175.0%) | $100.00 K(-200.0%) | $200.00 K(-200.0%) |
| Sept 1987 | - | -$100.00 K(-150.0%) | -$200.00 K(-50.0%) |
| Mar 1987 | - | $200.00 K(-166.7%) | -$400.00 K(0.0%) |
| Dec 1986 | -$400.00 K(+33.3%) | -$300.00 K(+200.0%) | -$400.00 K(+33.3%) |
| Sept 1986 | - | -$100.00 K(-50.0%) | -$300.00 K(+200.0%) |
| June 1986 | - | -$200.00 K(-200.0%) | -$100.00 K(<-9900.0%) |
| Mar 1986 | - | $200.00 K(-200.0%) | $0.00(-100.0%) |
| Dec 1985 | -$300.00 K(-250.0%) | -$200.00 K(-300.0%) | -$300.00 K(<-9900.0%) |
| Sept 1985 | - | $100.00 K(-200.0%) | $0.00(-100.0%) |
| June 1985 | - | -$100.00 K(0.0%) | -$100.00 K(-200.0%) |
| Mar 1985 | - | -$100.00 K(-200.0%) | $100.00 K(-50.0%) |
| Dec 1984 | $200.00 K(-33.3%) | - | - |
| Dec 1984 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| June 1984 | - | $100.00 K | $100.00 K |
| Feb 1984 | $300.00 K | - | - |
FAQ
- What is GT Biopharma annual net profit?
- What is the all time high annual net income for GT Biopharma?
- What is GT Biopharma annual net income year-on-year change?
- What is GT Biopharma quarterly net profit?
- What is the all time high quarterly net income for GT Biopharma?
- What is GT Biopharma quarterly net income year-on-year change?
- What is GT Biopharma TTM net profit?
- What is the all time high TTM net income for GT Biopharma?
- What is GT Biopharma TTM net income year-on-year change?
What is GT Biopharma annual net profit?
The current annual net income of GTBP is -$7.60 M
What is the all time high annual net income for GT Biopharma?
GT Biopharma all-time high annual net profit is $9.77 M
What is GT Biopharma annual net income year-on-year change?
Over the past year, GTBP annual net profit has changed by +$13.29 M (+63.62%)
What is GT Biopharma quarterly net profit?
The current quarterly net income of GTBP is -$3.41 M
What is the all time high quarterly net income for GT Biopharma?
GT Biopharma all-time high quarterly net profit is $26.86 M
What is GT Biopharma quarterly net income year-on-year change?
Over the past year, GTBP quarterly net profit has changed by -$995.00 K (-41.18%)
What is GT Biopharma TTM net profit?
The current TTM net income of GTBP is -$12.35 M
What is the all time high TTM net income for GT Biopharma?
GT Biopharma all-time high TTM net profit is $13.77 M
What is GT Biopharma TTM net income year-on-year change?
Over the past year, GTBP TTM net profit has changed by -$2.13 M (-20.84%)